BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Díaz-Rubio E. Vascular endothelial growth factor inhibitors in colon cancer. Adv Exp Med Biol. 2006;587:251-275. [PMID: 17163170 DOI: 10.1007/978-1-4020-5133-3_20] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Arias JI, Aller MA, Arias J. Cancer cell: using inflammation to invade the host. Mol Cancer 2007;6:29. [PMID: 17437633 DOI: 10.1186/1476-4598-6-29] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
2 Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008;21 Suppl 2:S23-S30. [PMID: 18437170 DOI: 10.1038/modpathol.2008.14] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
3 McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
4 Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yoshioka T, Okano Y, Moriwaki H, Kozawa O. Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells. Eur J Pharmacol 2011;650:145-50. [PMID: 20959118 DOI: 10.1016/j.ejphar.2010.10.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tai J, Wang G, Liu T, Wang L, Lin C, Li F. Effects of siRNA targeting c-Myc and VEGF on human colorectal cancer Volo cells. J Biochem Mol Toxicol 2012;26:499-505. [PMID: 23169760 DOI: 10.1002/jbt.21455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
6 Raatschen HJ, Fu Y, Brasch RC, Pietsch H, Shames DM, Yeh BM. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 2009;44:265-70. [PMID: 19346961 DOI: 10.1097/RLI.0b013e31819f1b60] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
7 Hernández-Pedro NY, Rangel-López E, Vargas Félix G, Pineda B, Sotelo J. An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis 2013;2013:716813. [PMID: 24294521 DOI: 10.1155/2013/716813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
8 Aplin AC, Fogel E, Zorzi P, Nicosia RF. Chapter 7 The Aortic Ring Model of Angiogenesis. Angiogenesis - In Vitro Systems. Elsevier; 2008. pp. 119-36. [DOI: 10.1016/s0076-6879(08)02007-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
9 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
11 Khan G, Merajver S. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opinion on Investigational Drugs 2009;18:541-8. [DOI: 10.1517/13543780902845622] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
12 Bekaii-Saab T. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. Clin Colorectal Cancer 2009;8:135-40. [PMID: 19632927 DOI: 10.3816/CCC.2009.n.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
13 Huang EH, Wicha MS. Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med. 2008;14:503-509. [PMID: 18929507 DOI: 10.1016/j.molmed.2008.09.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]